S&P 500   3,446.40 (+0.32%)
DOW   28,305.41 (+0.34%)
QQQ   284.00 (-0.07%)
AAPL   115.82 (-0.90%)
MSFT   214.11 (-0.32%)
FB   277.78 (-0.34%)
GOOGL   1,602.94 (+1.07%)
AMZN   3,157.47 (-0.86%)
TSLA   432.62 (+2.36%)
NVDA   534.41 (-1.22%)
BABA   306.66 (-0.43%)
CGC   19.79 (+1.54%)
GE   7.66 (+4.64%)
MU   54.28 (+1.82%)
AMD   79.76 (+0.71%)
T   28.18 (+5.46%)
F   8.07 (+2.80%)
ACB   4.76 (-1.86%)
GILD   59.99 (-0.37%)
NFLX   483.41 (-1.15%)
BA   167.25 (+2.07%)
NIO   27.29 (-2.05%)
DIS   127.87 (+0.98%)
S&P 500   3,446.40 (+0.32%)
DOW   28,305.41 (+0.34%)
QQQ   284.00 (-0.07%)
AAPL   115.82 (-0.90%)
MSFT   214.11 (-0.32%)
FB   277.78 (-0.34%)
GOOGL   1,602.94 (+1.07%)
AMZN   3,157.47 (-0.86%)
TSLA   432.62 (+2.36%)
NVDA   534.41 (-1.22%)
BABA   306.66 (-0.43%)
CGC   19.79 (+1.54%)
GE   7.66 (+4.64%)
MU   54.28 (+1.82%)
AMD   79.76 (+0.71%)
T   28.18 (+5.46%)
F   8.07 (+2.80%)
ACB   4.76 (-1.86%)
GILD   59.99 (-0.37%)
NFLX   483.41 (-1.15%)
BA   167.25 (+2.07%)
NIO   27.29 (-2.05%)
DIS   127.87 (+0.98%)
S&P 500   3,446.40 (+0.32%)
DOW   28,305.41 (+0.34%)
QQQ   284.00 (-0.07%)
AAPL   115.82 (-0.90%)
MSFT   214.11 (-0.32%)
FB   277.78 (-0.34%)
GOOGL   1,602.94 (+1.07%)
AMZN   3,157.47 (-0.86%)
TSLA   432.62 (+2.36%)
NVDA   534.41 (-1.22%)
BABA   306.66 (-0.43%)
CGC   19.79 (+1.54%)
GE   7.66 (+4.64%)
MU   54.28 (+1.82%)
AMD   79.76 (+0.71%)
T   28.18 (+5.46%)
F   8.07 (+2.80%)
ACB   4.76 (-1.86%)
GILD   59.99 (-0.37%)
NFLX   483.41 (-1.15%)
BA   167.25 (+2.07%)
NIO   27.29 (-2.05%)
DIS   127.87 (+0.98%)
S&P 500   3,446.40 (+0.32%)
DOW   28,305.41 (+0.34%)
QQQ   284.00 (-0.07%)
AAPL   115.82 (-0.90%)
MSFT   214.11 (-0.32%)
FB   277.78 (-0.34%)
GOOGL   1,602.94 (+1.07%)
AMZN   3,157.47 (-0.86%)
TSLA   432.62 (+2.36%)
NVDA   534.41 (-1.22%)
BABA   306.66 (-0.43%)
CGC   19.79 (+1.54%)
GE   7.66 (+4.64%)
MU   54.28 (+1.82%)
AMD   79.76 (+0.71%)
T   28.18 (+5.46%)
F   8.07 (+2.80%)
ACB   4.76 (-1.86%)
GILD   59.99 (-0.37%)
NFLX   483.41 (-1.15%)
BA   167.25 (+2.07%)
NIO   27.29 (-2.05%)
DIS   127.87 (+0.98%)
Log in
NASDAQ:GENE

Genetic Technologies Stock Forecast, Price & News

$3.37
-0.03 (-0.88 %)
(As of 10/22/2020 12:16 PM ET)
Add
Compare
Today's Range
$3.32
Now: $3.37▼
$3.40
50-Day Range
$3.24
MA: $3.53▼
$4.03
52-Week Range
$1.41
Now: $3.37▼
$10.30
Volume722 shs
Average Volume3.01 million shs
Market Capitalization$45.66 million
P/E RatioN/A
Dividend YieldN/A
Beta2.64
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.38 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GENE
Previous Symbol
CUSIPN/A
CIK1166272
Webwww.gtgcorporate.com
Phone011-61-3-8412-7000
EmployeesN/A

Debt

Debt-to-Equity Ratio0.02
Current Ratio10.88
Quick Ratio10.81

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales4,565.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.65 per share
Price / Book5.18

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares13,548,000
Market Cap$45.66 million
Next Earnings DateN/A
OptionableOptionable
$3.37
-0.03 (-0.88 %)
(As of 10/22/2020 12:16 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

How has Genetic Technologies' stock been impacted by COVID-19?

Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GENE shares have increased by 42.8% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19.

Are investors shorting Genetic Technologies?

Genetic Technologies saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 145,600 shares, a drop of 75.5% from the September 15th total of 594,500 shares. Based on an average daily volume of 7,270,000 shares, the short-interest ratio is presently 0.0 days.
View Genetic Technologies' Short Interest.

Who are some of Genetic Technologies' key competitors?

Some companies that are related to Genetic Technologies include GENFIT S A/ADR (GNFT), Ayala Pharmaceuticals (AYLA), Axcella Health (AXLA), DBV TECHNOLOGIE/S (DBVT), LogicBio Therapeutics (LOGC), Solid Biosciences (SLDB), BiomX (PHGE), Applied Genetic Technologies (AGTC), Cardiff Oncology (TROV), Gamida Cell (GMDA), Cidara Therapeutics (CDTX), Windtree Therapeutics (WINT), Windtree Therapeutics (WINT), Protara Therapeutics (TARA) and Erytech Pharma (ERYP).
View all competitors.

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), Opko Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Genetics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX).

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)
  • Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. Director
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec.

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $3.37.

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $45.66 million and generates $10,000.00 in revenue each year.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtgcorporate.com.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 011-61-3-8412-7000 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.